<DOC>
	<DOCNO>NCT02262741</DOCNO>
	<brief_summary>This multicenter , open-label , dose-exploration dose-expansion study evaluate safety , tolerability , antitumor activity , PK , pharmacodynamics , immunogenicity MEDI4736 combination tremelimumab subject recurrent/metastatic squamous cell carcinoma head neck .</brief_summary>
	<brief_title>A Phase I Study Evaluate Safety , Tolerability Efficacy MEDI4736 ( Durvalumab ) With Tremelimumab Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>1 . Male female subject 2 . 18 year old 3 . Histologically cytologically confirm recurrent metastatic squamous cell carcinoma head neck ( oral cavity , oropharynx , hypopharynx larynx ) incurable local therapy . 4 . Subjects treatmentnaive pretreated ( prior antiPD1 antiPDL1 require ) recurrent/metastatic setting . 5 . Subject eligibility base PDL1 expression determine specify IHC assay . 1 . Any concurrent chemotherapy , immunotherapy , biologic , hormonal therapy cancer treatment , receipt last dose approve anticancer therapy within 21 day 2 . Concurrent prior use immunosuppressive medication within 14 day 3 . Active prior document autoimmune inflammatory disease within 3 year exception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>